Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers
Science Advances · 14.08.2026 · 12 (33)
DOI: 10.1126/sciadv.aee2305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 14.08.2026. Verfasst von Jonathan Gallego-Rudolf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Douglas Research Centre, McGill University, Montreal, Canada. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIA NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Alzheimer’s disease (AD) develops silently for years before symptoms emerge, making early identification of at-risk individuals essential for prevention trials and early intervention. We tested whether combining neurophysiological, imaging, and blood biomarkers improves prediction of progression to mild cognitive impairment (MCI) in cognitively unimpaired older adults with a family history of AD ( n = 102; 31 progressors; mean follow-up of 5.9 years). Magnetoencephalography, magnetic resonance imaging, plasma biomarkers, and amyloid and tau positron emission tomography each captured complementary aspects of disease biology. Multimodal models predicted progression more accurately than demographic and genetic factors alone. Higher MEG alpha power was associated with increased near-term risk, whereas higher gamma activity predicted lower near-term risk; both effects weakened over time. Higher neocortical amyloid burden predicted increasing risk over follow-up, whereas plasma biomarkers and entorhinal tau predicted higher risk without significant time-varying effects. These findings support a time-sensitive multimodal framework for identifying cognitively unimpaired individuals at risk of MCI due to AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Douglas Research Centre, McGill University, Montreal, Canada.
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada.
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
ORCID-Profile: Jonathan Gallego-Rudolf, Alex I Wiesman, Yara Yakoub, Henrik Zetterberg, Kaj Blennow, Sylvain Baillet, Sylvia Villeneuve
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- NIBIB NIH HHS
- National Institutes of Health
- Alzheimer's Association
- Horizon Europe
- Canadian Institutes of Health Research
- Vetenskapsrådet
Zitieren
APA
Gallego-Rudolf, J., Wiesman, A. I., Yakoub, Y., Zetterberg, H., Blennow, K., Baillet, S., Villeneuve, S., & PREVENT-AD Research Group (2026). Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers. Science Advances, 12(33). https://doi.org/10.1126/sciadv.aee2305
Vancouver
Gallego-Rudolf J, Wiesman AI, Yakoub Y, Zetterberg H, Blennow K, Baillet S, et al. Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers. Science Advances. 2026;12(33). doi:10.1126/sciadv.aee2305
BibTeX
@article{GallegoRudolf2026,
author = {Gallego-Rudolf, Jonathan and Wiesman, Alex I and Yakoub, Yara and Zetterberg, Henrik and Blennow, Kaj and Baillet, Sylvain and Villeneuve, Sylvia and PREVENT-AD Research Group, PREVENT-AD Research Group},
title = {Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {33},
doi = {10.1126/sciadv.aee2305}
}
EUVIMED